New Technology and Hands-on Workshops Demonstrate Commitment to the Optimal Care of Patients with Spinal Deformity
SAN DIEGO, CA – July 12, 2016 – NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced it will participate at the 23rd International Meeting on Advanced Spine Technologies (IMAST), being held July 13 – July 16 in Washington, D.C.
NuVasive is committed to transforming and advancing spine surgery and has provided support to the Scoliosis Research Society (SRS) and IMAST, emphasizing the continued need for investment of research and education in the field of spinal deformities.
Pat Miles, president and chief operating officer of NuVasive, commented, “We are excited about the progress we have made to transform spine surgery and to help advance the care of patients with spinal deformity. NuVasive’s leading portfolio has revolutionized the treatment of adult deformity and the Company has increased its focus to better support pediatric and adolescent deformity. We remain committed to providing surgeons market-leading innovation that delivers the best possible patient outcomes.”
BASE Interfixated Titanium System Introduction
In addition to featuring its comprehensive portfolio of advanced spine technologies, NuVasive will showcase its newest titanium implant, the BASE Interfixated ALIF system. With a rich clinical history, titanium implants have a proven strength profile and improved osteointegration properties compared to other available materials. NuVasive’s BASE Interfixated ALIF system is a key addition to the integrated Global Alignment (iGA™) platform offering versatile fixation options, a distinctive locking mechanism and an anatomic hyperlodotic implant design to help rebuild the spinal foundation.
NuVasive IMAST Participation Details
NuVasive continues to support surgeon education through numerous hands-on workshops of its iGA platform, ALIF and XLIF® Anterior Column Realignment™ and the MAGEC® system.
Additional details on NuVasive’s IMAST workshops include:
- Surgical Solutions for Achieving Global Sagittal Alignment with Intraoperative Assessment Technology
- Wednesday, July 13, 17:00 – 19:00, Salon 15, Marriott Marquis
- Serena Hu, M.D., Bobby Kalantar, M.D., Tyler Koski, M.D., Justin Smith, M.D., Juan S. Uribe, M.D.
- Anterior Column Realignment with Computer-assisted Surgery
- Thursday, July 14, 12:30 – 13:30, Salon 15, Marriott Marquis
- Serena Hu, M.D., Rajiv Sethi, M.D., Christopher Shaffrey, M.D.
- MAGEC: Best Practices
- Thursday, July 14, 17:15 – 18:15, Judiciary Square, Marriott Marquis
- Suken Shah, M.D., Peter Sturm, M.D.
The Company will showcase and demonstrate its market-leading technologies at NuVasive Booth #16 on the IMAST exhibit floor.
NuVasive, Inc. (NASDAQ: NUVA) is a world leader in minimally invasive, procedurally-integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes. NuVasive’s highly differentiated, procedurally-integrated solutions include access instruments, implantable hardware and software systems for surgical planning and reconciliation technology that centers on achieving the global alignment of the spine. With $811 million in revenues (2015), NuVasive has an approximate 1,900 person workforce in more than 40 countries around the world. For more information, please visit nuvasive.com.
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA™ platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
# # #